Hologic (NASDAQ:HOLX) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other equities research analysts have also recently weighed in on HOLX. Royal Bank of Canada reaffirmed a “hold” rating and set a $42.00 price objective on shares of Hologic in a research report on Friday, September 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Hologic in a research report on Monday, October 2nd. Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 price objective (down previously from $48.00) on shares of Hologic in a research report on Monday, October 9th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $44.00 price objective (down previously from $49.00) on shares of Hologic in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Hologic presently has an average rating of “Buy” and a consensus price target of $48.79.

Hologic (NASDAQ:HOLX) traded up $0.16 during mid-day trading on Friday, hitting $43.71. 3,060,034 shares of the company traded hands, compared to its average volume of 1,908,935. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. Hologic has a fifty-two week low of $35.76 and a fifty-two week high of $46.80. The firm has a market capitalization of $12,006.02, a P/E ratio of 16.56, a PEG ratio of 2.08 and a beta of 0.95.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The business had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. During the same period in the prior year, the company posted $0.52 earnings per share. Hologic’s revenue was up 10.5% compared to the same quarter last year. equities research analysts anticipate that Hologic will post 2.15 earnings per share for the current fiscal year.

In other news, VP Karleen Marie Oberton sold 1,023 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Elaine Ullian sold 9,282 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Insiders sold 12,099 shares of company stock valued at $487,223 in the last three months. Company insiders own 0.79% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Hall Laurie J Trustee lifted its holdings in shares of Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares during the last quarter. Sentry Investment Management LLC lifted its holdings in shares of Hologic by 1.9% in the second quarter. Sentry Investment Management LLC now owns 18,491 shares of the medical equipment provider’s stock worth $839,000 after acquiring an additional 353 shares during the last quarter. Commonwealth Bank of Australia lifted its holdings in shares of Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 600 shares during the last quarter. Hancock Holding Co. lifted its holdings in shares of Hologic by 2.7% in the second quarter. Hancock Holding Co. now owns 27,379 shares of the medical equipment provider’s stock worth $1,242,000 after acquiring an additional 726 shares during the last quarter. Finally, Profund Advisors LLC lifted its holdings in shares of Hologic by 4.4% in the second quarter. Profund Advisors LLC now owns 26,993 shares of the medical equipment provider’s stock worth $1,225,000 after acquiring an additional 1,132 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Hologic (HOLX) Lowered to “Sell” at BidaskClub” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/13/hologic-holx-lowered-to-sell-at-bidaskclub.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.